Effects of changes in adipocyte hormones and visceral adipose tissue and the reduction of obesity-related comorbidities after laparoscopic sleeve gastrectomy in Japanese patients with severe obesity.
The aim of this study was to evaluate the relative contribution of serum adipokines and adipokines from the patient's omentum-derived adipocytes (PODAs) and visceral adipose tissue (VAT) of Japanese patients with severe obesity. Secondarily, we analyzed patients' metabolic changes after laparoscopic sleeve gastrectomy (LSG). Twenty-three LSG patients and 23 non-obese patients undergoing elective abdominal surgery were enrolled. The levels of adipokines in the serum and the PODAs were measured. The clinical and metabolic data were evaluated at 6 months after LSG. The mean serum leptin levels and the mean serum plasminogen activator inhibitor type-1 (PAI-1) levels were significantly greater (p < 0.001) and the mean adiponectin levels were significantly lower in the LSG group (p = 0.006). In the measurements of the PODAs, the mean leptin levels (p < 0.001) were significantly greater and the mean adiponectin levels (p < 0.001) were significantly lower in the LSG group. The mean BMI (-12 kg/m², p < 0.001) and mean VAT (-135.5 cm², p = 0.001) were significantly decreased after LSG. In nine patients with type 2 diabetes mellitus, the reduction in VAT correlated with the change in high-sensitivity C-reactive protein (p = 0.006) and the homeostasis model of assessment of insulin resistance (p = 0.001). After 6 months, LSG markedly improved most obesity-related comorbidities. Our results suggest that LSG may contribute to VAT reduction, improved adipocyte hormone levels, and changes in gut physiology and endocrinology.
Department of Surgery, Iwate Medical University School of Medicine, Morioka 020-8505, Japan.
Akira
A
Umemura
Akira
A
Sasaki
Hiroyuki
H
Nitta
Koki
K
Otsuka
Takayuki
T
Suto
Go
G
Wakabayashi
D054392:Adipokines / Q000097:blood / Q000378:metabolism*; D050154:Adiposity; D000328:Adult; D015992:Body Mass Index; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004038:Diet, Reducing; D005260:Female; D005500:Follow-Up Studies; D015391:Gastroplasty; D006801:Humans; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat / Q000378:metabolism* / Q000473:pathology; D007564:Japan; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000150:complications / Q000178:diet therapy / Q000378:metabolism / Q000601:surgery*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000378:metabolism; D011446:Prospective Studies; D015431:Weight Loss
D054392:Adipokines; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human